Skip to main content
  • FDA Advisory Panel Gives Mixed Reviews on Symplicity Spyral RDN

    Panel agrees device is safe; bare majority says it’s effective and that benefits do not outweigh risks

    Medtronic’s Symplicity Spyral Renal Denervation (RDN) System is safe, members of a U.S. Food and Drug Administration (FDA) advisory panel said unanimously Wednesday, but they split on the device’s effectiveness and whether the benefits outweigh the risks.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details